# HB-adMSCs for the Treatment of Crohn's Disease

> **NCT07077746** · PHASE2 · RECRUITING · sponsor: **Hope Biosciences Research Foundation** · enrollment: 46 (estimated)

## Conditions studied

- Crohn Disease (CD)

## Interventions

- **DRUG:** HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- **DRUG:** 0.9% sodium chloride

## Key facts

- **NCT ID:** NCT07077746
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077746, "HB-adMSCs for the Treatment of Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07077746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*